36C24426Q0855.docx
DOCX document 25 KB Posted
- Solicitation number
- 36C24426Q0855
About this file
This is a Notice of Intent to Award a sole source contract. The Department of Veterans Affairs (VA) Regional Procurement Office East, Network Contracting Office 4, intends to award a contract to Adaptive Biotechnologies Corporation (1165 Eastlake Avenue E, Seattle, Washington 98109) for clonoSEQ Measurable Residual Disease (MRD) Testing services at the Pittsburgh VA Medical Center, located at University Drive, Pittsburgh, PA 15240. The contract will be awarded pursuant to FAR 6.103-1 using simplified acquisition procedures and will be firm-priced for a five-year period.
The clonoSEQ assay is a proprietary, FDA-cleared, patented molecular test developed and performed exclusively by Adaptive Biotechnologies for MRD detection in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and other lymphoid malignancies. Adaptive Biotechnologies is identified as the sole source provider of clonoSEQ MRD testing within the United States. The annual quantity requirement is 100 clonoSEQ MRD tests (Line Item 1). Although this is a sole source award notice, any responsible firm believing it can meet the requirement must submit written notification and capability statements prior to the stated response due date. Vendors must indicate whether they are direct suppliers, service providers, or authorized resellers/distributors and provide supporting evidence demonstrating their ability to perform the work.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Special Notice Special Notice
| SUBJECT* |
| Lab Testing Services - clonoSEQ Measurable Residual Disease Test Pittsburgh VA Medical Center - Pittsburgh, PA |
GENERAL INFORMATION
| CONTRACTING OFFICE’S ZIP CODE* |
| 19805 |
| SOLICITATION NUMBER* |
| 36C24426Q0855 |
| RESPONSE DATE/TIME/ZONE |
| 08-10-2026 8AM EASTERN TIME, NEW YORK, USA |
| ARCHIVE |
| 15 DAYS AFTER THE RESPONSE DATE |
| RECOVERY ACT FUNDS |
| N |
| PRODUCT SERVICE CODE* |
| Q301 |
| NAICS CODE* |
| 621511 |
| CONTRACTING OFFICE ADDRESS |
| Department of Veterans Affairs |
Network Contracting Office 4 1601 Kirkwood Hwy Wilmington, DE 19805
POINT OF CONTACT*
Contracting Officer Mickeya Linzie mickeya.linzie@va.gov 302-516-0009
ADDITIONAL INFORMATION
| AGENCY’S URL |
| https://www.va.gov/wilmington-health-care/ |
| URL DESCRIPTION |
| Wilmington VA Health Care |
| AGENCY CONTACT’S EMAIL ADDRESS |
| mickeya.linzie@va.gov |
| EMAIL DESCRIPTION |
| Mickeya Linzie | Contracting Officer |
DESCRIPTION
NOTICE OF INTENT TO AWARD SOLE SOURCE: The Department of Veterans Affairs (VA) Regional Procurement Office East (RPOE), Network Contracting Office 4 (NCO 4) intends to award a sole source contract pursuant to RFO FAR 6.103-1 to Adaptive Biotechnologies Corporation located at 1165 Eastlake AVE E, Seattle, Washington 98109. Simplified acquisition procedures will be used, and the resulting contract will be firm priced for a five-year period.
The Pittsburgh VA Medical Center requires a contractor to provide clonoSEQ Measurable Residual Disease (MRD) Testing. This service shall be provided for the Department of Veterans Affairs, Pittsburgh VA Medical Center, located at University Drive, Pittsburgh, PA 15240. The clonoSEQ assay is provided exclusively by Adaptive Biotechnologies and is a proprietary, FDA-cleared, patented molecular test developed and performed exclusively by Adaptive Biotechnologies for MRD detection in bone marrow from patients with multiple myeloma and B-cell acute lymphoblastic leukemia (B-ALL), and in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). It is also a CLIA-validated laboratory developed (LDT) test for diffuse large B-cell lymphoma (DLBCL) and other lymphoid malignancies. Adaptive Biotechnologies is the sole source provider of clonoSEQ MRD testing within the United States. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet the VA facility’s needs.
| Line Item |
| Description |
| Annual Quantity |
| 1 |
| ClonoSEQ MRD Testing |
| 100 |
THIS NOTICE IS NOT A REQUEST FOR COMPETITIVE QUOTES; however, any responsible firm that believes it can meet the requirement shall give written notification and capability statements prior to the response due date and time. Vendors shall indicate if they are the direct supplier or service provider of the items and/or authorized reseller/distributor. Supporting evidence shall be furnished in sufficient detail to demonstrate the ability to perform the requirement and shall include relevant experience along with the applicable contract number(s), total contract dollar amount, contract period of performance, details of the relevant supply and/or services, and customer point of contact with corresponding telephone number and email address.
Responses shall include following information:
1. Company Name
2. SAM UEI Number
3. Company’s Address
4. Point of Contact Information (title, phone number and email address)
5. Business Size
Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based on responses to this notice is solely within the discretion of the Government. Information provided will not be returned.
Responses are due by Monday, 8/10/2026 at 8:00 AM Eastern Standard Time. No submissions will be accepted after this date and time. Responses shall be submitted via email to Mrs. Mickeya Linzie at mickeya.linzie@va.gov.
The NAICS code for this acquisition is 621511 (Medical Laboratories) and the size standard is $41.5 million.
End of Document
| *= Required Field |
| Special Notice |
Special Notice
File details come from the government source that posted it. Updated .